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PKD1 = protein kinase D1
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156SUMMARYate
avy
tiv
lar
sistThe authors used 52 nonfailing and failing human hearts to develop a simple, high throughput left ventricular myocardial
slice model that is stable by ATP and viability assays for at least 3 days. The model supports studies of signaling,
contraction, and viral transduction. They use the model to show for the ﬁrst time that the alpha-1A-adrenergic receptor,
which is present at very low abundance in the human myocardium, activates cardioprotective ERK with nanomolar EC50 in
failing heart slices and stimulates a positive inotropic effect. This model should be useful for translational studies, to test
whether molecules discovered in basic experiments are functional in the human heart. (J Am Coll Cardiol Basic Trans
Science 2016;1:155–67) Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B asic and pre-clinical research has identiﬁednumerous signaling molecules that might beefﬁcacious targets for drugs to treat heart
failure and myocardial disease (1). Translation of
these ﬁndings to clinical use could be facilitated if
the activity of these signaling molecules in human
ventricular myocytes was known. Isolated or cultured
human ventricular myocytes are useful for assays of
contraction and calcium handling (2–4). However,
surprisingly few studies use myocytes for biochem-
ical signaling assays, such as immunoblot (5,6).
One challenge with human ventricular myocytes
is the technical difﬁculty of isolation and the rela-etively low cell yields, making it difﬁcult
to do biochemical assays with numerous
replicates.
Isolated right ventricular trabeculae can
assay protein phosphorylation (7), but avail-
ability of trabeculae with the requisite small
size can be limiting (5). Chopped or hand-cut
myocardial pieces can also serve to explore
signaling (8,9), but limited viability, tech-
nical difﬁculty, or applicability to other as-
says, such as contraction, are limitations.SEE PAGE 168As an alternative approach to a human
biochemical signaling model, we studied thin
slices made from cores of left ventricular (LV)
myocardium. Thin slices have a long history
of use in other tissues, but there is minimal
precedent in heart, especially human (10).
Others describe human myocardial slices, but
there is no report of biochemical signaling,
likely due in part at least to limited stability
(11) or low numbers of samples (12,13).
Here, we describe a simple, reproducible,
high-throughput method to generate large
numbers of slices from cores of human LV
myocardium. We show that these slices are
stable and viable over several days, ampletime to assay signaling, contraction, and viral trans-
duction. As a test case, we study the effects of the
highly selective a1A-adrenergic receptor (AR) agonist
A61603. The a1A-AR is expressed in human myocar-
dium, but levels are very low, only 3% of total
adrenergic receptors (ARs) in the nonfailing human
LV, and 7% in the failing LV (14). Whether this low
level of a1A-ARs mediates detectable signaling or
function in the human myocardium is unknown. The
slice model shows for the ﬁrst time that human LV
a1A-ARs couple to ERK activation with high potency,
and also stimulate a positive inotropic response.
METHODS
PATIENTS. With the approval of the University of
California, San Francisco (UCSF), Committee for
Human Research, we obtained LV free wall tissue from
hearts removed at the time of transplant at UCSF, or
from organ donors whose hearts were not transplanted
for technical reasons. Full informed consent was ob-
tained from all UCSF transplant recipients before sur-
gery. The Donor Network West (formerly California
Transplant Donor Network) provided the unused
donor hearts and obtained informed consent from the
donor’s next of kin. Hearts were collected and trans-
ported to the laboratory in cold cardioplegia.
MAJOR EQUIPMENT. We used the following major
equipment for slice preparation and culture, all from
Alabama Research and Development (Munford, Ala-
bama): coring press (MD5000/53000); cylindrical
coring tool 8-mm diameter (MP0144); tissue embed-
ding unit (MD2299); Krumdieck tissue slicer
(MD4000); titanium meshes (MD0036); and slice
incubation unit (MD2500).
HEART COLLECTION. Hearts were explanted, and
the coronary arteries were immediately perfused via
the aorta with 1 l of ice-cold cardioplegia solution.
Complete blood washout was visualized. Hearts were
transported to the laboratory in ice-cold cardioplegia,
typically within 2 h after explant.
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157Cardioplegia for heart collection (Plegisol, 0409-
7969-05, Hospira, Lake Forest, Illinois): NaCl 110
mmol/l; KCl 16 mmol/l; CaCl2-2H2O 1.2 mmol/l;
NaHCO3 10 mmol/l; MgSO4-6H2O 16 mmol/l; that is
ice-cold (pH 7.8) and sterile.
CORING. Working on an open bench in ice-cold car-
dioplegia, 2-cm by 2-cm sections were cut from the
middle of the LV free wall, and 8-mm diameter cores
were generated using a coring press with an 8-mm
cylindrical coring tool. Areas with obvious LV scar
were avoided. Care was taken to cut the cores
perpendicular to the myoﬁber long axis. After coring,
a razor blade was used to remove fat and trabeculae
from the epicardial and endocardial surfaces. Cores
were embedded in 2% low melting temperature
agarose using the tissue embedding unit.
Agarose embedding buffer for cores: slicing buffer
(in the following text); low melting agarose 20 mg/ml
(Agarose II, 0815, Amresco, Solon, Ohio); sterile,
stored at 40C, and poured over the core in ice-cold
tissue embedding unit.
SLICING. The embedded core was oriented in the
Krumdieck tissue slicer with the endocardial surface
toward the blade, such that the cutting plane was
parallel to the myocyte long axis; a supplied weight
maintained downward pressure. Slice thickness was
set at 250 mm. The instrument passed the core
repeatedly and automatically across a replaceable
stainless steel blade while immersed in 4C, sterile
buffer. Circulating buffer ﬂoated the resultant slices
into a glass trap and a collecting tray.
Modiﬁed calcium-free Tyrode’s for heart slicing:
NaCl 111 mmol/l; KCl 16 mmol/l; HEPES 10 mmol/l;
NaHCO3 4.2 mmol/l; MgSO4-7H2O 0.4 mmol/l; glucose
5.6 mmol/l; 2,3-butanedione monoxime (BDM)
(B0753, Sigma-Aldrich, St. Louis, Missouri) 20 mmol/l;
(pH 7.2) at 4C in air. Components are added to sterile
water and ﬁlter-sterilized.
CALCIUM REINTRODUCTION. Slices were transferred
using a cut-off pipette into a 50-ml tube with ice-cold
calcium reintroduction buffer. After 10 min, addi-
tional CaCl2 was added at 10-min intervals to bring
the [Ca] successively to 25, 50, 100, 200, 400, 700,
and 1,000 mmol/l.
Calcium reintroduction buffer: Modiﬁed calcium-
free Tyrode’s as in the preceding text. Additionally:
blebbistatin (ab120425, Abcam, Cambridge, Massa-
chusetts) 0.1 mmol/l; BDM 40 mmol/l; adenosine
triphosphate (ATP) 2 mmol/l; ice-cold, sterile (pH 7.2),
and in air.
SLICE CULTURE. Using wide forceps to lift the slices
from underneath without damage (Millipore ﬁlter
forceps #XX6200006P, EMD Millipore, Billerica,Massachusetts), 2 to 4 slices were placed onto a tita-
nium mesh in each well of a 6-well culture tray with 2
ml of culture medium. Four trays were placed on a
dedicated slice incubation unit in a standard culture
incubator at 37C with 2% CO2. The slice incubation
unit rotated slices through air alternating with me-
dium at 1 rpm. Slices were harvested at intervals for
assays, without a change in medium.
Culture medium: MEM Eagle with Hanks’ Balanced
Salt Solution; HEPES 10 mmol/l; ATP 2 mmol/l; peni-
cillin 50 U/ml; vitamin B12 1.5 mmol/l; bovine calf
serum 10% (HyClone SH30073.03, GE Healthcare Life
Sciences, Logan, Utah); blebbistatin (Abcam ab120425)
0.1 mmol/l. Note: BDM (B0753, Sigma-Aldrich) 50
mmol/l was substituted for blebbistatin, only with
slices destined for contraction studies, because bleb-
bistatin has slow washout.
DOXORUBICIN DIFFUSION. Following slice genera-
tion, slices were incubated in culture medium
with doxorubicin HCl 100 mmol/l (#2252, Tocris
Bioscience, Minneapolis, Minnesota). After varying
times (1 min or longer), slices were rinsed in ice-cold
phosphate-buffered saline (PBS) for 10 min, then
incubated at 4C successively in 4% formaldehyde
overnight, 15% sucrose in PBS for 2 h, then 30%
sucrose in PBS overnight. Slices were embedded in
optical cutting temperature compound (OCT)
(#27050, Ted Pella, Redding, California), and 6-mm
cross sections were cut with a cryostat. Sections were
stained with wheat germ agglutinin 5 mg/ml for 15
min, washed in PBS for 10 min, air dried, and moun-
ted with Fluoromount-G (#0100-01, SouthernBiotech,
Birmingham, Alabama). Images were captured by
ﬂuorescent microscopy using a 20 objective, exci-
tation 540 to 525 nm, emission 605 to 655 nm.
BETA-MYOSIN HEAVY CHAIN AND PHOSPHO-ERK1/2
IMMUNOHISTOCHEMISTRY. Slices were ﬁxed using
4% formaldehyde and incubated at 4C in 4% sucrose
in PBS for 1 h, 15% sucrose in PBS for 4 h, and 30%
sucrose in PBS overnight. Slices were sunk into OCT
and snap-frozen in liquid nitrogen. Cryosections were
cut parallel to the long axis of the slice, resulting in
tangential sections, placed onto glass slides, washed
in PBS for 10 min, and then incubated in PBS with 1%
triton X100 for 30 min at room temperature. Excess
liquid was removed, and a barrier pen was used to
trace a border around the sections.
Sections were placed in a humidiﬁed chamber,
blocked with 125 ml of 5% goat serum in PBS, and
rocked for 20 min at room temperature. Excess ﬂuid
was suctioned off, and 125 ml of staining buffer with
primary antibody (Ab) was added (PBS with 0.2%
Triton X-100 and 1% goat serum with Ab to
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phospho-ERK [pERK]). Sections were incubated
overnight in a humidiﬁed chamber at 4C, washed 3
times with 125 ml of TBS-T for 2 min each, and washed
2 times with PBS for 5 min. Sections were then incu-
bated with 125 ml of staining buffer with secondary
Ab, rocked at room temperature for 1 h in a humidi-
ﬁed chamber, washed 4 times with 125 ml of TBS-T for
2 min each wash, and ﬁnally washed with PBS 2 times
for 5 min each wash. Excess ﬂuid was removed and
sections were mounted with Fluoromount-G.
The b-MyHC Ab was a mouse monoclonal clone
NOQ7.5.4D (#M8421, 1:200, Sigma-Aldrich). The pERK
Ab was a rabbit monoclonal against ERK1 phosphor-
ylated at threonine 202 and tyrosine 204, and ERK2
phosphorylated at threonine 185 and tyrosine 187
(D13.14.4E, XP, #4370; 1:50, Cell Signaling Technol-
ogy, Danvers, Massachusetts). The secondary Ab for
b-MyHC was goat anti-mouse IgG conjugated to Cy3
(#115-166-003, Jackson ImmunoResearch Labora-
tories, West Grove, Pennsylvania), and the secondary
Ab for pERK was goat anti-rabbit IgG conjugated to
Alexa 488 (#A11034, Life Technologies-Molecular
Probes, Carlsbad, California), both at 1:400.
ATP AND MTT ASSAYS FOR VIABILITY. Quantifying
ATP content and mitochondrial dehydrogenase
activity (MTT assay) assessed slice viability.
To measure ATP, slices were taken immediately
after slicing, or were cultured for varying times,
washed thoroughly in PBS, frozen in liquid nitrogen
in 1.5-ml Eppendorf tubes, and stored at 80C.
Liquid nitrogen was added to the tube, and slices
were pulverized to a ﬁne powder with a pestle, not
allowing thawing. Immediately, 1 ml of ice-cold 10%
trichloroacetic acid was added. Samples were allowed
to thaw on ice, then vortexed, and precipitated
protein was pelleted at 13,226  g for 10 min. The ATP-
containing supernatant was separated from the pellet
and neutralized with a 1:100 dilution of HEPES
10 mmol/l. ATP was quantiﬁed by luciferase assay
(CellTiter-Glo Luminescent Cell Viability Assay,
#G7572, Promega, Madison, Wisconsin), detected by
the GloMax-Multi þ Detection System (#9311-010,
Promega) against ATP standards 1 nmol/l to 1 mmol/l.
The protein pellet was solubilized in SDS 1% and
HEPES 0.1 mol/l, sonicated for 5 s, left at room tem-
perature overnight, and quantiﬁed by the Lowry
method against BSA. ATP was referenced to slice
protein.
To determine mitochondrial dehydrogenase activ-
ity, MTT reagent (MTT Cell Proliferation Assay, #30-
1010K, ATCC, Manassas, Virginia) 200 ml was added to
slices in 2 ml of culture medium for 30 min at 37C.The slices were rinsed in PBS, and frozen at 80C.
The purple formazan precipitate was solubilized in 1
ml of DMSO (#D5879, Sigma-Aldrich) for 1 h at 37C
with vortexing once at 30 min, and absorbance in
100 ml was quantiﬁed relative to DMSO alone, on the
GLOMAX Multiþ Detection System. Slices were dab-
bed dry with Kimwipes, and weighed. Absorbance
was referenced to slice wet weight, which was highly
correlated with slice protein by Bradford (r2 ¼ 0.9,
p < 0.0001, n ¼ 10).
IMMUNOBLOT FOR PHOSPHORYLATED PHOSPHO-
LAMBAN AND pERK. Slices in culture medium for 1
day were incubated with L-isoproterenol HCl (ISO)
(#I6504, Sigma-Aldrich), DL-propranolol HCl
(#318-98-9, Sigma-Aldrich), or A61603 (#1052, Tocris
Bioscience). After varying times, slices were rinsed,
frozen in liquid nitrogen in 1.5-ml Eppendorf tubes,
and stored at 80C. Liquid nitrogen was added to the
tube, and slices were pulverized to a ﬁne powder with
a pestle, not allowing thawing, sonicated 5 s in 0.75 ml
of 1% SDS with HEPES 100 mmol/l, phosphoSTOP (#04
906 837 001, Roche Applied Science, Indianapolis,
Indiana), and protease inhibitor (complete Mini,
#11836 153 001, Roche Applied Science), vortexed, and
centrifuged at 13,226 g for 5 min at room tempera-
ture. Protein in the supernatant was quantiﬁed by the
Lowry method, and 10 to 20 mg of protein per lane was
used in immunoblot for phosphorylated phospho-
lamban (pPLN) and pERK. Protein loading was
conﬁrmed by Coomassie blue staining of the blot.
The Ab for PLN phosphorylated at serine 16 was an
Upstate rabbit polyclonal Ab #07-052 (1:10,000, EMD
Millipore). The Ab for ERK1 phosphorylated at thre-
onine 202 and tyrosine 204, and ERK2 phosphory-
lated at threonine 185 and tyrosine 187 was a Cell
Signaling Technology rabbit monoclonal Ab #4370
(1:1,000). The Ab for total ERK1/2 was a Cell Signaling
rabbit polycloncal Ab #9102, and the Ab for total PLN
was an Upstate mouse monoclonal clone A1 #05-205.
The secondary Ab was horseradish peroxidase-linked
goat anti-rabbit IgG (#7074, 1:10,000, Cell Signaling
Technology) or horse anti-mouse IgG (#7076, 1:10,000
Cell Signaling Technology).
SLICE CONTRACTION. Linear strips approximately
300 to 400 mm wide were dissected from myocardial
slices in culture medium, then placed in a muscle
chamber (3  3  15 mm) and mounted on stainless
steel pins. One end of the strip was mounted to a
force transducer (AE-801, Kronex, Oakland, Califor-
nia), and the other end to a micromanipulator. Strips
were superfused at 5 ml/min for 1 h at room tem-
perature in Krebs-Henseleit solution (in mmol/l:
NaCl 112, KCl 5, MgCl2 1.2, glucose 10, NaHCO3 24,
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159Na2SO4 1.2, NaH2PO4 2.0, CaCl2 0.2), oxygenated with
95% O2, 5% CO2. The calcium level of the solution
was gradually increased to 1.8 mmol/l, and the
temperature was increased to 37C. The strip was
stimulated to contract at 0.2 Hz using platinum wire
electrodes at maximal voltage. Optimal length of
the strip was determined by adjusting the length
to achieve the highest force production. Strips
were stimulated with AR agonists as described in the
Results section, using A61603, phenylephrine (PE)
(#P-6126, Sigma-Aldrich), or ISO.
SLICE TRANSDUCTION WITH ADENOVIRUS. Slices
were incubated in culture medium on day 0 with
pAdEasy-1 (Stratagene, Agilent Technologies, Santa
Clara, California) with the CMV promoter driving
human protein kinase D1 (PKD1) with an N-terminal
green ﬂuorescent protein (GFP) tag. After 24 h culture
at 37C, slices were ﬁxed by shaking in 4% formal-
dehyde for 10 min at 4C and transferred to 4C PBS
for 72 h. Slices were treated with increasing concen-
trations of sucrose in PBS, embedded in OCT, and
cryosectioned at 6 mm with a cross-sectional
orientation.
Sections at room temperature were rinsed in PBS
for 10 min, permeabilized in 0.25% Triton PBS for
10 min, blocked with 5% normal goat serum in PBS for
1 h, rinsed in PBS twice for 10 min per rinse, incubated
1 h with Alexa 488-conjugated rabbit polyclonal Ab to
GFP (#A21311, Molecular Probes) diluted 1:400 in PBS,
rinsed in PBS twice for 10 min per rinse, and mounted
with Fluoromount-G. Fluorescent photomicrographs
were taken with an epiﬂuorescent microscope using
the green channel.
STATISTICS. Results are mean  SE. Dose-response
curves were ﬁt and signiﬁcant differences (p < 0.05)
were tested in GraphPad Prism v5.0d (GraphPad
Software, La Jolla, California). Regular 2-way analysis
of variance was used for Figure 3, and 95% conﬁdence
limits were calculated for Figures 4 to 6. We used the
D’Agostino and Pearson omnibus test for normality.
RESULTS
DEVELOPMENT OF A HIGH-THROUGHPUT SLICE
MODEL FOR SIGNALING. We developed and vali-
dated the slice model over a period of 5 years, using
18 transplant recipient hearts (designated failing),
and 34 unused donor hearts (nonfailing). For failing
hearts, average patient age was 52 years (range 27 to
72 years), with 61% male. For nonfailing, the average
age was 56 years (range 19 to 72 years), with 65%
male. Most transplant patients were receiving
beta-blockers (22%), were treated with an LV assist
device (LVAD) (50%), or both (11%).Figure 1 illustrates slice generation and culture.
Each step of the procedure was modiﬁed and tested
during development, and a detailed ﬁnal protocol
is given in the Methods section. The Krumdieck in-
strument cut LV cores into slices 250 mm thick at a
rate ofw10 to 20 per min, and the slices ﬂoated into a
collection tray.
Calcium was gradually reintroduced to 1 mmol/l,
and 2 to 4 slices were placed on a titanium mesh in
each well of a 6-well culture tray with 2 ml of me-
dium. Four or more trays were placed on an inclined
incubation unit in a CO2 incubator at 37C, and the
slices were rotated alternately through air and me-
dium at 1 rpm. Slices were used for assays at intervals,
without a medium change.
An average 1.5-cm thick LV free wall core cut into
250 mm slices provided a maximum of w60 slices per
core. A single LV provided multiple LV cores; 2 to 3
cores produced w96 slices, which could be cultured
in four 6-well culture trays. Additional trays could
easily be added to increase throughput. After protocol
optimization, slices usable for experiments were ob-
tained in all hearts.
CHARACTERIZATION OF SLICE MORPHOLOGY,
DIFFUSION, AND VIABILITY. Figure 2A is a slice
schematic, illustrating key characteristics. The sche-
matic indicates that the plane of slicing was parallel
to the myocyte long axis; this is conﬁrmed in
Figures 2B and 2C. We estimated that each slice 8 mm
diameter and 250 mm thick contained approximately
356,000 myocytes. This estimate is based on mea-
surements of myocyte cross sectional area and length
in the slices, to obtain an average volume 26,500 mm3,
within the range found in prior studied of human
myocytes (15), and assumes that 25% of the slice is
extracellular volume (16,17). Thus the total number of
myocytes studied in an experiment with 96 slices was
about 34 million. Figure 2A also indicates that the
average slice wet weight was 8 mg, and the protein
amount by Bradford assay was 2 mg.
To assess slice morphology, we did immunohisto-
chemistry for b-MyHC, the main human myosin.
Figure 2B shows that slices after 2 d culture had well
aligned sarcomeres. Some wrinkling was evident, as
expected for unloaded myocardium. Supplemental
Figure 1 illustrates slice histology by hematoxylin
and eosin staining.
A slice thickness of 250 mm was the best for both
ease of cutting and rapid diffusion into the center of
the slice, to avoid hypoxia. To measure diffusion, we
took advantage of the red autoﬂuorescence of doxo-
rubicin, which is transported into cell nuclei (18).
Figure 2C shows that doxorubicin was seen in myo-
cyte nuclei at the center of the slice within 1 min,
FIGURE 1 Slice Generation and Culture
(A) A coring tool is used to punch an 8-mm diameter “core” from pieces of left ventricular free wall, perpendicular to myoﬁber orientation.
(B) The core is trimmed, imbedded in agarose, and placed in a holder of the Krumdieck slicer, submerged in cold slicing buffer. (C) The core is
passed across a razor blade at the bottom of the core holder to cut slices, and cold buffer delivers them into a receiving dish. (D) Slices “curl”
slightly after cutting. (E) Two to 4 slices are placed on a titanium mesh in each well of a culture tray. (F) Four or more trays are placed on an
inclined rotator in the incubator, so that slices rotate through air and medium interfaces.
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the top and bottom surfaces of the slice have mostly
intact myocytes.
We used 2 assays to monitor slice viability, ATP
and MTT. ATP on day 0, immediately after cutting,was 32  3 nmol/mg protein in slices from nonfailing
hearts (n ¼ 20), and 46  8 in slices from failing hearts
(n ¼ 9, p ¼ 0.13 Student unpaired t test). The ATP
level for nonfailing agrees extremely well with hu-
man heart studies (mean 31 nmol/mg, range 23 to
FIGURE 2 Slice Characteristics
Slices are cut parallel to the myocyte long axis. (A) Slice dimensions, measured wet weight and protein, and estimated myocyte number (based on average volume
26,500 mm3). (B) Beta-myosin heavy chain (b-MyHC) immunohistochemistry in a section tangential to a nonfailing slice shows well-aligned sarcomeres, with some
wrinkling by culture day 2, likely caused by contraction. (C) A nonfailing slice cross section stained with wheat germ agglutinin shows doxorubicin (red autoﬂuorescence)
in myocyte nuclei in the center of the slice within 1 min of incubation, and clean top and bottom surfaces.
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FIGURE 3 Human Myocardial Slices Are Viable for at Least
3 Days in Culture
Left ventricular myocardial slices were cultured as in the Methods
section for the number of days indicated. Day 0 indicates slices
immediately after cutting. As a negative control, slices were killed
by prolonged anoxia, H2O2, or methanol. Adenosine triphosphate
(ATP) (A) and MTT (B)were measured in duplicate slices from each
heart. ATP duplicates agreed within an average 20%; and MTT,
within an average 9%. MTT values in arbitrary units (AU) per mg
after day 0 were normalized to the MTT value on day 0 in the same
experiment. Numbers are the numbers of hearts; values aremean
SE. There are no signiﬁcant differences with time or between
nonfailing and failing (regular 2-way analysis of variance: ATP p ¼
0.23, 0.77, 0.54 for interaction, group, and time, respectively; MTT
p ¼ 0.91, 0.99, and 0.44 for interaction, group, and time,
respectively).
FIGURE 4 b-Adrenergic Activation of PLN in Human
Heart Slices
After 1 day in culture, duplicate left ventricular myocardial slices
were treated for 15 min with varying doses of the b-adrenergic
agonist isoproterenol (ISO), without or with the nonselective b-
antagonistpropranolol (PROP).Phosphorylationofphospholamban
(PLN) at S16 was measured by immunoblot. A and B are from a
nonfailing heart. (A) ISO doses. A blot of total PLN (tPLN) shows
equal loading. (B) PROP inhibits ISO. (C) Concentration-response
relationships for the indicated number of hearts, with duplicate
slices for each heart at each dose; mean SE. The maximum effect
values (Emax) for both failing (21) and nonfailing (17) are different
from 1.0 (p< 0.05 by conﬁdence limits). Half-maximal effective
concentration (EC50) and Emax values for failing and nonfailing do
not differ by curveﬁtting. These failing patientswere treatedwith a
left ventricular assist device.
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16238 nmol/mg, n ¼ 5) (19–23). The ATP level in failing
slices was higher than that seen in failing hearts in the
same previous 5 studies (mean 25 nmol/mg, range 20-
33). Figure 3A shows that slice ATP did not change
signiﬁcantly over 3 days in culture, in nonfailing or
failing heart slices. Figure 3B shows the MTT assay for
mitochondrial dehydrogenase activity was also not
changed signiﬁcantly over time.
Together, these data indicated good slice
morphology, diffusion, and viability over at least 3
days, ample time to do experiments.
b-AR SIGNALING TO PLN. As a ﬁrst test of signaling
in the slice model, we sought to determine whetherwe could detect by immunoblot the expected b-AR
stimulation of PLN phosphorylation. Duplicate slices
after 1 day in culture were treated for 15 min with
varying concentrations of the nonselective b-AR
agonist ISO, in the absence or presence of the
nonselective antagonist propranolol. Slices were
rinsed and frozen in liquid nitrogen, then proteins
were extracted in SDS with protease and phosphatase
inhibitors, and used in immunoblot. Figure 4A shows
that ISO stimulated robust phosphorylation of the
protein kinase A target site serine 16. Figure 4B shows
that the ISO effect was inhibited by a low concentra-
tion of propranolol, conﬁrming b-AR dependence.
Figure 4C shows concentration-response data. In
FIGURE 5 a1A-AR Activation of ERK in Human Heart Slices
After 1 day in culture, duplicate left ventricular myocardial slices were treated for 15 min with varying doses of the alpha-1A-adrenergic receptor (a1A-AR) agonist
A61603 (A6). ERK dually phosphorylated at Thr202 and Tyr204 of Erk1 (Thr185 and Tyr187 of Erk2) was measured by immunoblot. (A) pERK immunoblot with varying
A61603 doses in a nonfailing slice; a Coomassie-stained gel and a blot of total ERK (tERK) show equal loading. (B) Concentration-response relationships for total pERK in
the indicated number of failing and nonfailing hearts, with duplicate slices for each heart at each dose; mean  SE. Emax values for both failing and nonfailing are
different from 1.0 (p < 0.05 by conﬁdence limits). Failing and nonfailing Emax and EC50 do not differ by curve ﬁtting. Three failing patients were treated with a left
ventricular assist device, and 1 with carvedilol. (C) pERK immunohistochemistry in failing slices shows pERK in interstitial cells (ISCs) with both vehicle and A61603, and
diffusely increased pERK in myocyte cytoplasm with A61603 1 mmol/l 15 min (e.g., asterisks). Abbreviations as in Figure 5.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 3 , 2 0 1 6 Thomas et al.
A P R I L 2 0 1 6 : 1 5 5 – 6 7 Human Alpha-1A-Adrenergic Signaling
163
FIGURE 6 The a1A-AR Stimulates a Positive Inotropic Effect in Human Myocardium
Stripsw0.12mm2werecutfromleftventricularslicesofnonfailingheartsoncultureday1andpacedat
0.2Hzand37C. ISO,phenylephrine (PE), andA6were addedas indicated.Dataare from2hearts. (A)
Examplesoforiginal contraction traces. (B) ISOconcentration-response relationship for the increase in
developedforce (systolic diastolic).Baselinesystolic forcewas1.4millinewtons (mN)/mm2;diastolic
forcewas0.8mN/mm2anddidnotchangewith ISO.The increase inforce issigniﬁcantlydifferent from
100% (p< 0.05 by conﬁdence limits). (C) The increase in developed force with A6 and PE. Abbre-
viations as in Figure 5.
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164slices from both nonfailing and failing hearts, ISO
stimulated serine 16 pPLN with a very low
half-maximal effective concentration (EC50) (3 nmol/l)
and a robust maximum (17- to 21-fold). These failing
hearts were treated with an LVAD, perhaps explaining
the preserved b-AR signaling.
a1A-AR SIGNALING TO ERK. To test a1A-AR signaling,
we treated slices after 1 day in culture with the highlyselective a1A-AR agonist A61603. The a1A-AR activates
ERK in myocytes, and ERK activation is required for
cardioprotective effects of the a1A-AR in mouse ven-
tricular myocytes (24). A61603 is inactive when the
a1A-AR is knocked out (25); and A61603 does not acti-
vate ERK in a1A KO myocytes (Myagmar and Simpson
unpublished data, 2016).We quantiﬁed ERK activation
by immunoblot for dual threonine-tyrosine phos-
phorylation of ERK1/2. Figure 5A shows a marked in-
crease in pERK with A61603 as low as 1 nmol/l for 15
min. Group data for failing and nonfailing heart slices
in Figure 5B indicate in both amaximum 1.8- to 2.2-fold
increase in pERK, with an EC50 5 nmol/l (n ¼ 4 to 5).
Failing and nonfailing concentration-response curves
did not differ.
Whereas PLN is myocyte speciﬁc, ERK is present in
myocytes and nonmyocytes, and the latter contribute
to ERK phosphorylation in diseased heart (26). To
examine whether the increase in pERK by immuno-
blot was localized to myocytes, we did pERK immu-
nohistochemistry on frozen sections after 15 min of
treatment with A61603. Figure 5C shows bright pERK
ﬂuorescence in interstitial cells in slices treated with
vehicle or A61603, and a clear increase in pERK in
myocyte cytoplasm with A61603, indicating ERK
activation in myocytes.
b- AND a1-AR STIMULATED CONTRACTION. To test
contraction, we cut small strips from the slices, and
mounted them in vitro, paced at 0.2 Hz and 37C in
medium with 1.8 mmol/l calcium. Slices assigned to
contraction were cultured with BDM, but not bleb-
bistatin, because the latter had slow washout.
A maximum dose of the subtype-nonselective
agonist phenylephrine (PE) (10 mmol/l) or a maximum
dose of the a1A-subtype-selective agonist A61603
(100 nmol/l) activated a1-ARs; acute inotropic re-
sponses were quantiﬁed when contraction force stabi-
lized, typically w20 min after addition. Varying doses
of the subtype-nonselective agonist ISO activated
b-ARs, and acute responses were measured w150 to
200 s after ISO addition, when force reached a plateau.
Figure 6A illustrates with raw contraction traces
that ISO, PE, and A61603 each had a positive inotropic
effect in the strips cut from the slices. Figure 6B has
summary data showing that ISO increased developed
force by w275%, with an EC50 225 nmol/l. Maximum
systolic force was low, w2 mN/mm2, most likely
because myocytes are oriented in different directions
from top to bottom through the slice. A61603 100
nmol/l increased developed force by 82%, one-third
as much as ISO (Figure 6B). The nonselective a1-AR
agonist PE increased developed force by only 34%,
TABLE 1 Comparison of Human Myocardial Slices vs. Isolated or Cultured
Ventricular Myocytes
Slice Advantages Slice Disadvantages
Much easier Cell heterogeneity
(need cell-speciﬁc assays)
More reproducible Used less (fewer comparison data)
Much higher throughput (estimated 356,000 myocytes
per slice, up to 96 slices with total 34 million myocytes
per four 6-well culture trays; multiple sets of 4 trays
per culture incubation unit) vs. 1 to 2 million cells per
isolation
Initial expense of equipment
Unbiased (no selection for healthier cells)
More physiological (paracrine and autocrine signaling
preserved)
Efﬁcient use of hearts (more cells per heart)
Enables biochemistry, histology, and physiology
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165perhaps because of concomitant negative inotropic
effects of the a1B-AR, which is also stimulated by PE,
but not by A61603.
VIRAL TRANSDUCTION OF HUMAN MYOCARDIAL
SLICES. To test whether slices could be used for
transduction with virus, we did a pilot study with
1 heart. Slices were infected with adenovirus con-
taining PKD1 with an N-terminal GFP tag.
Supplemental Figure 2 shows GFP immunoreactivity
in every myocyte exposed to 250 plaque-forming
units of virus, the lowest amount tested, indicating
successful transduction.
DISCUSSION
We developed and validated a myocardial slice model
to study signaling in the human heart. This simple,
reproducible, high throughput approach generates a
large number of slices from LV myocardium that can
be used for biochemistry, contraction, and viral
transduction.
Myocyte morphology and viability are maintained
over at least 3 days, ample time to do assays. This
model could be useful for translational studies, to test
whether signaling molecules identiﬁed in animal
studies are active in human myocytes. As proof of
concept, we show for the ﬁrst time that the a1A-AR
mediates ERK activation and a positive inotropic ef-
fect in human LV myocardium.
Table 1 compares the advantages and disadvantages
of this new slice model, in comparison with isolated
and cultured ventricular myocytes. The advantages
with respect to other tissue preparations, for example,
trabeculae (as mentioned in the Introduction section),
include reproducibility, throughput, and validation in
biochemical and other assays. With this slice model, or
any tissue preparation, it is required to show that
observed signaling is in myocytes. We studied pPLN,
which is myocyte speciﬁc, and pERK, which is present
in all cell types. To show ERK activation in myocytes,
we used immunohistochemistry, and the immuno-
histochemistry approach should be useful in most
cases. This slice model also requires an initial equip-
ment outlay, for the coring press, Krumdieck slicer,
and culture incubation unit. We consider these
important to the success of the protocol.
Other aspects of the protocol we consider espe-
cially important for optimum slices include heart
perfusion and transport in cold cardioplegia, with
total time from explant to slicing <w4 h; slice cutting
parallel to the myocyte long axis; BDM  blebbistatin
in slice preparation and culture; and slice thickness
250 mm. Slice viability was improved by slow calcium
reintroduction and adding serum to the culturemedium. The detailed protocol we provide in the
Methods section should enable replication in other
laboratories.
In contrast with prior human myocardial slice re-
ports (11–13), our report is the ﬁrst used to study
biochemical signaling, includes the most hearts by
far, studies both failing and nonfailing, and presents a
detailed protocol. Only 1 other study used explants,
rather than biopsies, and included only 3 hearts (13).
One report studied electrophysiology and contraction
in slices cut from LV outﬂow tract biopsies of patients
having valve replacement; 4 to 20 slices were
obtained from each patient (12). The slices were
viable as long as 28 days by MTT assay, but the
ﬁbroblast marker vimentin was increased by 5-fold at
day 4 and by 18-fold by day 28 (12), raising the pos-
sibility that some of the MTT signal at 28 days was
from proliferating ﬁbroblasts. In addition, several
markers of myocyte differentiation were reduced
with time, including myosin light chain 2 mRNA,
visible cross striations, contractility, and action po-
tentials (12). These changes are consistent with the
observation that ﬁbroblast overgrowth can impair
myocyte differentiation (27). To minimize such time-
dependent changes, we advocate using the slices over
the ﬁrst few days, when the slices are most stable.
Using this model, we were able to discover novel
translational biology.
Speciﬁcally, the model enabled us to show for
the ﬁrst time to our knowledge that the a1A-AR is
active in signaling and contraction in human LV
myocardium, by measuring the effects of the highly
selective a1A-AR agonist A61603. The a1A-AR is
present at very low levels in human LV (as
mentioned in the Introduction section), and it was
unknown whether this low level could mediate
signaling. The robust ERK activation in failing and
nonfailing slices is notable, as well as a positive
PERSPECTIVES
TRANSLATIONAL OUTLOOK: Basic research is
identifying multiple potential targets for drugs to
treat heart failure and myocardial disease, but trans-
lation to clinical trials is very difﬁcult. Species
differences exist between humans and mice and other
pre-clinical models. Evidence that potential targets
are functional in human myocardium might facilitate
translation, but models to test signaling in human
myocardium are limited. We describe a simple,
reproducible, high-throughput human myocardial
slice model to study signaling. As proof of usefulness,
we show for the ﬁrst time that a very low abundance
cardioprotective receptor, the alpha-1A-adrenergic
receptor, is functional in nonfailing and failing human
myocardium.
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166inotropic effect that is one-third the magnitude of
ISO in nonfailing slices. The a1A-AR via ERK acti-
vation is protective in mouse myocytes (24), and
A61603 can prevent apoptosis in the mouse heart
in vivo (28). The present data support the possibility
that the protective effect of a1A activation in mouse
might extend to the human heart.
STUDY LIMITATIONS. A caveat is that signaling
ex vivo might not occur in vivo. However, approaches
to study signaling in the human myocardium in vivo
are lacking.
CONCLUSIONS
In summary, mouse models are valuable for investi-
gating molecular mechanisms of cardiac disease and
suggesting potential therapeutic targets. However,
fundamental differences between mouse and human
physiology raise uncertainty regarding the human
disease relevance of ﬁndings in mice. Therefore,
studies in human myocardium are essential but
challenging due in part to their difﬁculty and low
throughput. This model addresses an important need
in describing a simple, high throughput system to
study signaling in human myocardium, and reveals
for the ﬁrst that the a1A-AR is functional in the
human heart.
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